Study: Immunization program in UK has reduced HPV infections in young women

Each year around 2,000-2,500 women are diagnosed with cervical cancer in England, the most common cancer in women under 35. Infection with high-risk human papillomavirus (HR HPV) types 16 and 18 is responsible for around 70-80% of cervical cancers. A study conducted by Public Health England and presented today at the Society for General Microbiology's Annual Conference shows a reduction in these two HR HPV types - which are included in the HPV vaccines used - in sexually active young women in England.

Between 2010 and 2012, over 4000 samples were collected from young women receiving a chlamydia screen as part of the National Chlamydia Screening Programme in England. Prior to the HPV immunisation programme introduction, a survey showed around 1 in 5 sexually active women aged 16 to 18 were infected with at least one of the two HPV types included in vaccines. A similar survey conducted following the introduction of the programme showed the prevalence had dropped to 1 in 15 young women.

Post-immunisation prevalence of HPV types 16 and 18 infection was lowest among women aged 16 to 18 year old, the age group with the highest vaccination coverage. Prior to the immunisation programme, this age group was shown to have the highest prevalence of infection.

David Mesher, Public Health England, presenting the work at the conference, said: "This study provides an early indication that the national HPV immunisation programme is successfully reducing vaccine-type HPV infections in sexually active young women in England, and also suggests herd-immunity may be benefiting non-vaccinated young women and men.

"The data provide reassurance that the high efficacy against HPV infection in women reported in clinical trials can be effectively realised in practice, and in a programme achieving high coverage amongst young females. These data adds to our confidence that the HPV immunisation programme will achieve its aim of reducing cervical cancer."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Novel vaccination strategy shows promise in boosting immunity and controlling influenza spread in pigs